Pyxis Oncology (PYXS) Non-Current Deferred Tax Liability (2022 - 2024)

Pyxis Oncology (PYXS) has 3 years of Non-Current Deferred Tax Liability data on file, last reported at $2.2 million in Q3 2024.

• On a quarterly basis, Non-Current Deferred Tax Liability changed N/A year-over-year to $2.2 million in Q3 2024; TTM through Sep 2024 was $2.2 million, a N/A change from a year earlier, with the FY2023 full-year figure at $2.2 million, down 41.1% from the prior year.
• Non-Current Deferred Tax Liability for Q3 2024 stood at $2.2 million, roughly flat from $2.2 million in the prior quarter.
• Over the last five years, Non-Current Deferred Tax Liability for PYXS reached as high as $3.7 million in Q4 2022 and fell as low as $2.2 million in Q4 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $2.5 million across 3 years, with a median of $2.2 million in 2023.
• On a YoY basis, Non-Current Deferred Tax Liability climbed as much as 41.1% in 2023 and fell as far as 41.1% in 2023.
• Year by year, Non-Current Deferred Tax Liability stood at $3.7 million in 2022, then slumped by 41.1% to $2.2 million in 2023, then changed by 0.0% to $2.2 million in 2024.
• Per Business Quant data, the three most recent Non-Current Deferred Tax Liability figures were $2.2 million in Q3 2024, $2.2 million in Q2 2024, and $2.2 million in Q1 2024.